# Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome

Study · id `cardio:ct-nct07508254` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07508254](<https://clinicaltrials.gov/study/NCT07508254>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07508254

Browse, organ or system: Heart; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 120 participants.

## Technical summary

Registry record NCT07508254. Randomized; no masking; primary purpose treatment. Start 2026-05-01 (anticipated); primary completion 2026-10-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT07508254, source copy `cardio:ctgov-nct07508254-2026-04-09`, retrieved 2026-10-31)
- Planned start: 2026-05-01 (anticipated) (ClinicalTrials.gov record NCT07508254, source copy `cardio:ctgov-nct07508254-2026-04-09`, retrieved 2026-10-31)
- Primary completion: 2026-10-01 (anticipated) (ClinicalTrials.gov record NCT07508254, source copy `cardio:ctgov-nct07508254-2026-04-09`, retrieved 2026-10-31)
- Completion: 2026-10-31 (anticipated) (ClinicalTrials.gov record NCT07508254, source copy `cardio:ctgov-nct07508254-2026-04-09`, retrieved 2026-10-31)
- Countries: Pakistan (ClinicalTrials.gov record NCT07508254, source copy `cardio:ctgov-nct07508254-2026-04-09`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07508254-2026-04-09`, retrieved 2026-10-31)

## The registry's words

- Brief title: Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome
- Acronym: TLD-ACS
- Condition: Acute Coronary Syndromes (ACS)
- Condition: Hypercholesterolemia
- Intervention (Drug): Atorvastatin 40 Mg Oral Tablet
- Intervention (Drug): Ezetimibe 10 mg
- Intervention (Drug): Bempedoic Acid 180 MG Oral Tablet
- Lead sponsor: Punjab Institute of Cardology
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)

## Provenance

Content hash: bf4f954a3b12a59635d406231dbfd00ff6a0fe36fda4f980a33218781c422036
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
